



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/Incn20>

Synthesis of Base Substituted 2-Hydroxy-3-(purin-9-yl)-propanoic Acids and 4-(Purin-9-yl)-3-butenic Acids

Petra Doláková^a, Milena Masojídková^a & Antonín Holý^{a, b}

^a Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Praha, Czech Republic

^b Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 6 Dejvice, Praha, 16610, Czech Republic

Published online: 19 Dec 2011.

To cite this article: Petra Doláková, Milena Masojídková & Antonín Holý (2003) Synthesis of Base Substituted 2-Hydroxy-3-(purin-9-yl)-propanoic Acids and 4-(Purin-9-yl)-3-butenic Acids, *Nucleosides, Nucleotides and Nucleic Acids*, 22:12, 2145-2160, DOI: [10.1081/NCN-120026636](https://doi.org/10.1081/NCN-120026636)

To link to this article: <http://dx.doi.org/10.1081/NCN-120026636>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

Synthesis of Base Substituted 2-Hydroxy-3-(purin-9-yl)-propanoic Acids and 4-(Purin-9-yl)-3-butenic Acids[#]

Petra Doláková,[‡] Milena Masojídková, and Antonín Holý*

Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the
Czech Republic, Praha, Czech Republic

ABSTRACT

Alkylation of 6-chloropurine and 2-amino-6-chloropurine with bromoacetaldehyde diethyl acetal afforded 6-chloro-9-(2,2-diethoxyethyl)purine (**3a**) and its 2-amino congener (**3b**). Treatment of compounds **3** with primary and secondary amines gave the N⁶-substituted adenines (**5a–5c**) and 2,6-diaminopurines (**5d–5f**). Hydrolysis of **3** resulted in hypoxanthine (**6a**) and guanine (**6b**) derivatives, while their reaction with thiourea led to 6-sulfanylpurine (**7a**) and 2-amino-6-sulfanylpurine (**7b**) compounds. Treatment with diluted acid followed by potassium cyanide treatment and acid hydrolysis afforded 6-substituted 3-(purin-9-yl)- and 3-(2-aminopurin-9-yl)-2-hydroxypropanoic acids (**8–10**). Reaction of compounds **3** with malonic acid in aqueous solution gave exclusively the product of isomerisation, 6-substituted 4-(purin-9-yl)-3-butenic acids (**15**).

Key Words: Purines; Purine alkylation; Acyclic nucleosides; Malonic acid; 3-(Purin-9-yl)-2-hydroxypropanoic acids.

[#]In honor and celebration of the 70th birthday of Professor Leroy B. Townsend.

[‡]Part of the Diploma Thesis (P.D.), Faculty of Sciences, Charles University Prague (Czech Republic).

*Correspondence: Antonín Holý, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 6 Dežvice, Praha 16610, Czech Republic; Fax: 4202 220183560; E-mail: Holy@uochb.cas.cz.



INTRODUCTION


3-(Adenin-9-yl)-2-hydroxypropanoic acid (AHPA) (**1a**) is a powerful inactivator of S-adenosyl-L-homocysteine hydrolase.^[1] Hence it is endowed with a capacity to interfere with proliferating cells and systems which require massive SAM-mediated methylation reactions catalyzed by methyl transferases.^[2] Thus, it manifested strong chemosterilizing effect on certain insects,^[3] on differentiation of plant root cells^[4] and, also, an antiviral effect directed against minus stranded RNA viruses and poxviruses. The antiviral activity was enhanced by esterification, which increased the lipophilic character and penetrability of the compounds through the cell membranes.^[5] 2-Methylpropyl ester of AHPA (**1b**) was selected as the optimum candidate for detailed investigation.^[6] Its activity against vaccinia virus was higher compared to the parent acid, which formed therefrom in the cell pool by cytosolic enzymes. As expected, the target for AHPA action was the capping process (methylation of 5'-end-guanine of viral mRNA).^[7]

With the growing interest in compounds active against poxviruses we decided to look more closely on the structure~activity relationship in this field to find out whether there is not any additional mechanism of antiviral action besides the above-mentioned inhibition of methylation.

RESULTS

This article describes synthesis of racemic base-modified 3-(purin-9-yl)-2-hydroxypropanoic acids, mainly 6-substituted purine and 2-aminopurine derivatives. Recently, we have prepared several optically active compounds of this type by enantiospecific synthesis based on the alkylation of the bases with chiral oxiranecarboxylic acid esters.^[8] In the present case, we are applying the cyanohydrin synthesis from the appropriate 2-(purin-9-yl)ethanals, under the conditions used for the original preparation of AHPA and its congeners.^[9] The two key-compounds, the 6-chloropurine (**3a**) and the 2-amino-6-chloropurine (**3b**) derivatives were synthesized by treatment of the respective purine base with bromoacetaldehyde diethyl acetal in the presence of NaH, Cs₂CO₃ or DBU in DMF. Under these conditions, the alkylation was directed predominantly to the N9 position. The thus obtained key-intermediates (**3a**) and (**3b**) were treated with the appropriate amine solution (dimethylamine was replaced with dimethylammonium N,N-dimethylcarbamate). The N6-substituted 9-(2,2-diethoxyethyl) adenines (**5a–5c**) or 2,6-diaminopurines (**5d–5f**) were isolated and fully characterized. The DABCO-catalyzed alkaline hydrolysis of the 6-chloro derivatives (**3a**) and (**3b**) gave hypoxanthine (**6a**) and guanine derivative (**6b**), while their treatment with thiourea afforded the 6-sulfanylpurine (**7a**) and 2-amino-6-sulfanylpurine (**7b**) derivatives.^[10]

To perform the cyanohydrin synthesis, the 2,2-diethoxyethyl derivatives (**5a–5f**, **6a–6b**, **7a–7b**) were first heated with dilute inorganic acid to form the free aldehydes and the reaction mixtures were treated directly with KCN at neutral pH. Subsequent hydrolysis with dilute HCl afforded the base-modified 2-hydroxy-3-(purin-9-yl)propanoic acids (**8a–8f**, **9a–9b**, **10a–10b**). The deionized reaction products were finally purified by anion exchange chromatography (Sch. 1).



Scheme 1. (a) $\text{BrCH}_2\text{CH}(\text{OEt})_2, \text{Cs}_2\text{CO}_3/\text{DMF}, 100^\circ\text{C}$; (b) $\text{R}_1\text{R}_2\text{NH}$ or R_1NH_2 , [or $(\text{CH}_3)_2\text{NH}^+(\text{CH}_3)_2\text{N-COO}^-$]; (c) (1) H^+ , (2) KCN (3) H^+ ; (d) DABCO , aq. K_2CO_3 ; (e) thiourea.

In our earlier article,^[9] we have discovered that the treatment of 9-(2,2-diethoxyethyl)adenine (**11a**) with malonic acid in boiling aqueous solution does not afford the expected 4-(adenin-9-yl)-2-butenic acid (**12**) but gives exclusively the isomeric 4-(adenin-9-yl)-3-butenic acid (**13**). We have postulated the mechanism of this




isomerisation based on addition of water to the primary reaction product and its subsequent elimination in either direction. It was considered plausible that the markedly low water solubility of compound (**13**) could shift this equilibrium in favor of this isomer. This speculation was supported by the fact that the homologue, 2-(adenin-9-yl)-1,1-diethoxypropane (**11b**) gives with malonic acid in water the postulated intermediate, 4-(adenin-9-yl)-3-hydroxypropanoic acid (**14**) as the only reaction product. Having in hand the above series of 2,2-diethoxyethyl purines (**5a–5f**, **6a–6b**, **7a–7b**) we have further investigated this reaction. However, in all cases examined solely the 6-substituted 4-(purin-9-yl)-3-butenic acids (**15a–15j**) were obtained, disregarding the solubility of the product in the course of the reaction. Removal of excess malonic acid and final purification were performed by ion exchange chromatography.

Untypical formation of β,γ -unsaturated acids from malonic acid and aldehydes was already described in the literature.^[11] However, in all such cases the reaction was performed in non-aqueous solvents in the presence of the tertiary base or, in the neat tertiary base. Thus, to explain the formation of the β,γ -unsaturated acids from 2,2-diethoxyethyl purines and malonic acid in water we are suggesting the above water addition-elimination mechanism. The driving force of this reaction could well be the formation of the enamine product with extended π -orbital overlap involving the heteroaromatic system (Sch. 2).

In conclusion, we have synthesized a series of base-substituted 2-hydroxy-3-(purin-9-yl)propanoic acids by cyanohydrin synthesis from 3-(purin-9-yl)ethanals. The latter compounds were obtained by transformations of 9-(2,2-diethoxyethyl)-6-chloropurine or 2-amino-6-chloropurine prepared by alkylation of the bases with bromoacetaldehyde diethyl acetal. The 2,2-diethoxyethyl derivatives give with aqueous malonic acid 6-substituted 4-(purin-9-yl)-3-butenic acids.

The biological examination of these compounds is not yet finished. However, we have not encountered in this group any compound with prominent cytostatic activity and/or antiviral activity against vaccinia virus.



Scheme 2. (a) CH₂(COOH)₂, H₂O reflux.

EXPERIMENTAL

Unless otherwise stated, solvents were evaporated at 40°C/2 kPa and compounds were dried overnight at 2 kPa over P₂O₅. Melting points were determined on a Büchi Melting Point B-545 apparatus and are uncorrected. TLC was performed on plates of kieselgel 60 F254 (Merck) in systems S1 (chloroform-methanol 95:5), S2 (chloroform-methanol 9:1), S3 (ethyl acetate-acetone-ethanol-water 4:1:1:1) and S4 (ethyl acetate-petroleum ether 1:1). Paper electrophoresis was performed on a Whatman No. 3 MM paper at 40 V/cm for 1 h in 0.05 M triethylammonium hydrogencarbonate, pH 7.5; the electrophoretic mobilities were referenced to uridine 3'-phosphate. NMR spectra were measured on an FT NMR spectrometer Varian UNITY 500 (¹H at 500 MHz and ¹³C at 125.7 MHz) in dimethyl sulfoxide-*d*₆. Chemical shifts (δ ppm) and coupling constants (*J*, Hz) were obtained by the first-order analysis of the spectra. Mass spectra were measured on a ZAB-EQ (VG Analytical) spectrometer using FAB (ionization by Xe, accelerating voltage 8 kV, glycerol matrix).

General Methods

Deionization of the Reaction Mixture. The solution of reaction products in water (20–25 mL) was applied on a column of Dowex 50 × 8 (100 mL, H⁺ form), and the column was washed with water until the drop of the UV absorption (254 nm) and acid reaction of the eluate. The standard elution rate was 3 mL/min. Elution was continued with 10% ammonia, and the UV-absorbing eluate was collected and evaporated.

Purification by Column Chromatography on Dowex 1 × 2. Unless stated otherwise, 100 mL columns of Dowex 1 × 2 (acetate form) were used. The sample was dissolved in water (20–25 mL), alkalified with concentrated aqueous ammonia to pH 9–9.5, and applied on the column. Elution with water (3 mL/min) was continued until the drop of the initial UV absorption (254 nm) of the eluate. The column was then eluted with a linear gradient of acetic acid.

6-Chloro-9-(2,2-diethoxyethyl)purine (3a) and 6-Chloro-7-(2,2-diethoxyethyl)purine (4a). To the stirred mixture of (2a) (7.7 g, 50 mmol) and cesium carbonate (8.1 g, 25 mmol) in DMF (150 mL) was added bromoacetaldehyde diethylacetal (11.6 mL, 75 mmol). The mixture was heated under stirring at 100°C for 24 h with exclusion of moisture. The reaction mixture was filtered while hot through Celite, taken down at 50°C/13 Pa and codistilled with toluene (3 × 50 mL) and ethanol (2 × 50 mL). The residue was extracted with boiling chloroform (500 mL), filtered through Celite and evaporated. The residue in methanol (200 mL) was treated with silica gel (150 mL), evaporated and applied on a column of silica gel (600 mL) in ethyl acetate-petroleum ether mixture (1:2). The column was eluted with ethyl acetate-petroleum ether mixture (1:2–1:1). The crystallization from ethyl acetate-petroleum ether afforded 5.6 g (42%) of compound (3a), white crystals, mp 85°C, R_F = 0.66 (S1). ¹H NMR: 8.79 (s, 1H, H-2); 8.62 (s, 1H, H-8); 4.89 (t, 1H, *J*(2',1') = 5.0, H-2'); 4.40 (d, 2H,



$J(1',2')=5.0$, H-1'); 3.64 and 3.45 (dq, 2H, $J(\text{CH}_2, \text{CH}_3)=7.1$, $J(\text{gem})=9.6$, O-CH₂); 1.01 (t, 6H, $J(\text{CH}_3, \text{CH}_2)=7.1$, CH₃). ¹³C NMR: 152.32 (C-4); 151.74 (C-2); 149.15 (C-6); 148.04 (C-8); 130.64 (C-5); 99.26 (C-2'); 62.59 (2C, O-CH₂); 46.01 (C-1'); 15.21 (2C, CH₃). FAB MS, m/z : 271.2 [M + H]. For C₁₁H₁₅N₄O₂Cl calcd: C, 48.80; H, 5.58; N, 20.70; Cl, 13.10; O, 11.82%; found: C, 48.93; H, 5.60; N, 20.60; Cl, 13.19; O, 11.68%. Further elution of the column with ethyl acetate-petroleum ether (1:1) gave, after crystallization from ethyl acetate-petroleum ether, compound (**4a**) (0.73 g, 5.5%), white crystals, mp = 60°C, $R_F=0.54$. ¹H NMR: 8.78 (s, 1H, H-2); 8.72 (s, 1H, H-8); 4.82 (t, 1H, $J(2',1')=5.0$, H-2'); 4.59 (d, 2H, $J(1',2')=5.0$, H-1'); 3.64 and 3.42 (dq, 2H, $J(\text{CH}_2, \text{CH}_3)=7.1$, $J(\text{gem})=9.6$, O-CH₂); 0.99 (t, 6H, $J(\text{CH}_3, \text{CH}_2)=7.1$, CH₃). ¹³C NMR: 161.57 (C-4); 151.87 (C-2); 151.63 (C-8); 142.51 (C-6); 122.45 (C-5); 100.40 (C-2'); 63.23 (2C, O-CH₂); 48.85 (C-1'); 15.20 (2C, CH₃). FAB MS, m/z : 271 [M + H]. For C₁₁H₁₅N₄O₂Cl calcd: C, 48.80; H, 5.58; N, 20.70; Cl, 13.10; O, 11.82%; found: C, 48.72; H, 5.54; N, 20.54; Cl, 13.18; O, 12.02%.

2-Amino-6-chloro-9-(2,2-diethoxyethyl)purine (3b) and 2-Amino-6-chloro-7-(2,2-diethoxyethyl)purine (4b). These compounds were prepared from 2-amino-6-chloropurine (**2b**) (8.5 g, 50 mmol) by the same procedure as compounds (**3a**) and (**4a**). The silica gel column was eluted with chloroform (1 L) and then with chloroform-methanol mixture (98:2). The crystallization from ethyl acetate-petroleum ether afforded 8.5 g (59%) of compound (**3b**), white crystals, mp = 139.2°C, $R_F=0.54$ (S1). ¹H NMR: 8.04 (s, 1H, H-8); 6.94 (s, 2H, NH₂); 4.80 (t, 1H, $J(2',1')=5.4$, H-2'); 4.13 (d, 2H, $J(1',2')=5.4$, H-1'); 3.63 and 3.42 (dq, 2H, $J(\text{CH}_2, \text{CH}_3)=7.1$, $J(\text{gem})=9.6$, O-CH₂); 1.025 (t, 6H, $J(\text{CH}_3, \text{CH}_2)=7.1$, CH₃). ¹³C NMR: 160.00 (C-2); 154.43 (C-4); 149.45 (C-6); 143.73 (C-8); 123.14 (C-5); 99.37 (C-2'); 62.48 (2C, O-CH₂); 45.44 (C-1'); 15.28 (2C, CH₃). FAB MS, m/z : 286 [M + H]. For C₁₁H₁₆N₅O₂Cl calcd: C, 46.24; H, 5.64; N, 24.51; Cl, 12.41; O, 11.20%; found: C, 46.22; H, 5.75; N, 24.29; Cl, 12.25; O, 11.49%. Further elution of the column, and crystallization from ethyl acetate-petroleum ether, afforded 1.7 g (12%) of compound (**4b**), white crystals, mp = 163°C, $R_F=0.41$ (S1). ¹H NMR: 8.28 (s, 1H, H-8); 6.64 (brs, 2H, NH₂); 4.76 (t, 1H, $J(2',1')=5.4$, H-2'); 4.37 (d, 2H, $J(1',2')=5.4$, H-1'); 3.63 and 3.39 (dq, 2H, $J(\text{CH}_2, \text{CH}_3)=7.1$, $J(\text{gem})=9.6$, O-CH₂); 1.01 (t, 6H, $J(\text{CH}_3, \text{CH}_2)=7.1$, CH₃). ¹³C NMR: 164.24 (C-4); 160.02 (C-2); 150.45 (C-8); 143.66 (C-6); 115.21 (C-5); 100.49 (C-2'); 63.12 (2C, O-CH₂); 48.64 (C-1'); 15.27 (2C, CH₃). FAB MS, m/z : 286 [M + H]. For C₁₁H₁₆N₅O₂Cl calcd: C, 46.24; H, 5.64; N, 24.51; Cl, 12.41; O, 11.20%; found: C, 46.32; H, 5.75; N, 24.61; Cl, 12.42; O, 10.90%.

9-(2,2-Diethoxyethyl)-6-(dimethylamino)purine (5a). The solution of compound (**3a**) (4.1 g, 15 mmol) and dimethylamonium N,N-dimethylcarbamate (5.8 mL, 45 mmol) in acetonitrile (120 mL) was refluxed for 0.5 h with exclusion of moisture. The mixture was evaporated and the residue codistilled with ethanol (2 × 50 mL). The residue was dissolved in chloroform (100 mL) and washed with water (3 × 50 mL) and the water was washed with chloroform (2 × 50 mL). Organic phase was dried with MgSO₄ and evaporated. The crystallization from ethyl acetate-petroleum ether afforded 4.54 g (95%) of compound (**5a**), white crystals, mp = 65°C,

$R_F = 0.75$ (S1). ^1H NMR: 8.22 (s, 1H, H-2); 8.07 (s, 1H, H-8); 4.83 (t, 1H, $J(2',1') = 5.4$, H-2'); 4.23 (d, 2H, $J(1',2') = 5.4$, H-1'); 3.63 and 3.41 (dq, 2H, $J(\text{CH}_2, \text{CH}_3) = 7.1$, $J(\text{gem}) = 9.6$, O-CH₂); 3.44 (brs, 6H, N-CH₃); 1.02 (t, 6H, $J(\text{CH}_3, \text{CH}_2) = 7.1$, CH₃). ^{13}C NMR: 154.34 (C-6); 151.95 (C-2); 150.60 (C-4); 140.22 (C-8); 119.03 (C-5); 99.56 (C-2'); 62.36 (2C, O-CH₂); 45.40 (C-1'); 39.00 (br, N-CH₃); 38.00 (br, N-CH₃); 15.22 (2C, CH₃). FAB MS, m/z : 280 [M + H]. For C₁₃H₂₁N₅O₂ calcd: C, 55.90; H, 7.58; N, 25.07; O, 11.45%; found: C, 55.74; H, 7.69; N, 24.91; O, 11.66%.

2-Amino-9-(2,2-diethoxyethyl)-6-(dimethylamino)purine (5d). This compound was prepared from compound (3b) (4.3 g, 15 mmol) by the procedure described for compound (5a). Yield 4.07 g (92%), white crystals, mp = 108–109°C, $R_F = 0.86$ (S3). ^1H NMR: 7.64 (s, 1H, H-8); 5.84 (brs, 2H, NH₂); 4.76 (t, 1H, $J(2',1') = 5.5$, H-2'); 4.04 (d, 2H, $J(1',2') = 5.5$, H-1'); 3.63 and 3.39 (dq, 2H, $J(\text{CH}_2, \text{CH}_3) = 7.0$, $J(\text{gem}) = 9.6$, O-CH₂); 3.37 (brs, 6H, N-CH₃); 1.04 (t, 6H, $J(\text{CH}_3, \text{CH}_2) = 7.0$, CH₃). ^{13}C NMR: 159.70 (C-2); 154.85 (C-6); 153.03 (C-4); 137.05 (C-8); 113.41 (C-5); 99.67 (C-2'); 62.31 (2C, O-CH₂); 45.08 (C-1'); 43.20 and 37.90 (N-CH₃); 15.35, 2C (CH₃). FAB MS, m/z : 295.2 [M + H]. For C₁₃H₂₂N₆O₂ calcd: C, 53.05; H, 7.53; N, 28.55; O, 10.87%; found: C, 53.00; H, 7.75; N, 28.51; O, 10.74%.

***N*⁶-Substituted 6-Amino-9-(2,2-diethoxyethyl)purines and 2,6-Diamino-9-(2,2-diethoxyethyl)purines.** *General procedure.* A mixture of compound (3a) (2.17 g, 8 mmol) [for preparation of *N*⁶-substituted 6-amino-9-(2,2-diethoxyethyl)purines] or compound (3b) (2.28 g, 8 mmol) [for preparation of *N*⁶-substituted 2,6-diamino-9-(2,2-diethoxyethyl)purines], ethanol (80 mL) and primary or secondary amine (4 equivalents) was refluxed for 1–6 h with exclusion of moisture. The course of the reaction was checked with TLC in systems S1 and S3. After completion, the mixture was evaporated and the residue codistilled with ethanol (2 × 50 mL). The residue was dissolved in chloroform (50 mL), washed with water (2 × 50 mL) and the water was washed with chloroform (2 × 50 mL). Organic phase was dried with MgSO₄ and evaporated. The following compounds were prepared by this procedure:

6-(Cyclopropylamino)-9-(2,2-diethoxyethyl)purine (5b). Crystallized from ethyl acetate-petroleum ether, yield 2.0 g (86%) of white crystals, mp = 96.6°C, $R_F = 0.46$ (S2). ^1H NMR: 8.25 (brs, 1H, H-2); 8.05 (s, 1H, H-8); 7.89 (brs, 1H, NH); 4.84 (t, 1H, $J(2',1') = 5.4$, H-2'); 4.23 (d, 2H, $J(1',2') = 5.4$, H-1'); 3.63 and 3.41 (dq, 2H, $J(\text{CH}_2, \text{CH}_3) = 7.1$, $J(\text{gem}) = 9.6$, O-CH₂); 3.04 (m, 1H, N-CH); 1.02 (t, 6H, $J(\text{CH}_3, \text{CH}_2) = 7.1$, CH₃); 0.72 and 0.61 (m, 2H, C-CH₂). ^{13}C NMR: 155.65 (C-6); 152.56 (C-2); 149.50 (C-4); 141.28 (C-8); 118.91 (C-5); 99.61 (C-2'); 62.38 (2C, O-CH₂); 45.40 (C-1'); 27.88 (N-CH); 15.28 (2C, CH₃); 6.57 (2C, CH₂). FAB MS, m/z : 292.1 [M + H]. For C₁₄H₂₁N₅O₂ calcd: C, 57.72; H, 7.26; N, 24.04; O, 10.98%; found: C, 57.63; H, 7.22; N, 23.96; O, 11.19%.

9-(2,2-Diethoxyethyl)-6-(pyrrolidin-1-yl)purine (5c). Crystallized from petroleum ether, yield 2.46 g (96%), white crystals, mp = 59–61°C, $R_F = 0.56$ (S1). ^1H NMR: 8.20 (s, 1H, H-2); 8.04 (s, 1H, H-8); 4.83 (t, 1H, $J(2',1') = 5.4$ (H-2')); 4.22 (d, 2H, $J(1',2') = 5.4$, H-1'); 4.05 and 3.60 (m, 2H, N-CH₂); 3.63 and 3.41



(dq, 2H, $J(\text{CH}_2, \text{CH}_3) = 7.1$, $J(\text{gem}) = 9.6$, O-CH₂); 1.97 and 1.91 (m, 2H, C-CH₂); 1.025 (t, 6H, $J(\text{CH}_3, \text{CH}_2) = 7.1$, CH₃). FAB MS, m/z : 306 [M + H]. For C₁₅H₂₃N₅O₂ calcd: C, 59.00; H, 7.59; N, 22.93; O, 10.48; found: C, 58.93; H, 7.74; N, 22.83; O, 10.50%.

2-Amino-6-(cyclopropylamino)-9-(2,2-diethoxyethyl)purine (5e). Crystallized from ethanol-ether, yield 1.92 g (78%), white crystals, mp = 164.2°C, $R_F = 0.49$ (S2). ¹H NMR: 7.61 (s, 1H, H-8); 7.28 (brs, 1H, NH); 5.87 (brs, 2H, NH₂); 4.76 (t, 1H, $J(2', 1') = 5.4$, H-2'); 4.03 (d, 2H, $J(1', 2') = 5.4$, H-1'); 3.63 and 3.39 (dq, 2H, $J(\text{CH}_2, \text{CH}_3) = 7.1$, $J(\text{gem}) = 9.6$, O-CH₂); 3.03 (m, 1H, N-CH); 1.04 (t, 6H, $J(\text{CH}_3, \text{CH}_2) = 7.1$, CH₃); 0.65 and 0.58 (m, 2H, C-CH₂). ¹³C NMR: 160.41 (C-2); 156.02 (C-6); 150.00 (C-4); 137.78 (C-8); 113.21 (C-5); 99.74 (C-2'); 62.32 (2C, O-CH₂); 45.06 (C-1'); 27.00 (N-CH); 15.34 (2C, CH₃); 6.55 (2C, CH₂). FAB MS, m/z : 307.1 [M + H]. For C₁₄H₂₂N₆O₂ calcd: C, 54.89; H, 7.24; N, 27.43; O, 10.44%; found: C, 54.73; H, 7.37; N, 27.32; O, 10.58%.

2-Amino-9-(2,2-diethoxyethyl)-6-(pyrrolidin-1-yl)purine (5f). Crystallized from ethyl acetate-petroleum ether, yield 2.2 g (88%) of white crystals, mp = 110.4°C, $R_F = 0.88$ (S3), $R_F = 0.14$ (S4). ¹H NMR: 7.61 (s, 1H, H-8); 5.80 (brs, 2H, NH₂); 4.76 (t, 1H, $J(2', 1') = 5.5$, H-2'); 4.03 (d, 2H, $J(1', 2') = 5.5$, H-1'); 3.96 and 3.55 (m, 2H, N-CH₂); 3.63 and 3.39 (dq, 2H, $J(\text{CH}_2, \text{CH}_3) = 7.1$, $J(\text{gem}) = 9.6$, O-CH₂); 1.89 (m, 4H, C-CH₂); 1.04 (t, 6H, $J(\text{CH}_3, \text{CH}_2) = 7.1$, CH₃). ¹³C NMR: 160.06 (C-2); 153.21 (C-6); 152.60 (C-4); 137.48 (C-8); 113.64 (C-5); 99.69 (C-2'); 62.28 (2C, O-CH₂); 48.20 and 47.00 (N-CH₂); 45.02 (C-1'); 25.15 and 24.00 (C-CH₂); 15.35 (2C, CH₃). FAB MS, m/z : 321.1 [M + H]. For C₁₅H₂₄N₆O₂ calcd: C, 56.23; H, 7.55; N, 26.23; O, 9.98%; found: C, 56.06; H, 7.65; N, 25.97; O, 10.32%.

9-(2,2-Diethoxyethyl)hypoxanthine (6a). The solution of (3a) (2.17 g, 8 mmol), K₂CO₃ (4.43 g, 32 mmol) and DABCO (1.8 g, 16 mmol) in water (25 mL) was stirred at reflux for 2 h, neutralized by addition of Dowex 50 × 8, alkalified with 10% ammonia and filtered. The resin was washed with water (200 mL) and 10% ammonia (200 mL). The filtrate was evaporated. The residue was extracted with boiling ethyl acetate, filtered, evaporated and applied on a silica gel column. The column was eluted with ethyl acetate-methanol (90:10). The crystallization from ethyl acetate-petroleum ether afforded 1.5 g (74%) of compound (6a), white solid, mp = 172.3–173.8°C, $R_F = 0.51$ (S2). ¹H NMR: 7.85 (s, 1H, H-2); 7.60 (s, 1H, H-8); 4.74 (t, 1H, $J(2', 1') = 5.6$, H-2'); 4.07 (d, 2H, $J(1', 2') = 5.6$, H-1'); 3.62 and 3.39 (dq, 2H, $J(\text{CH}_2, \text{CH}_3) = 7.1$, $J(\text{gem}) = 9.6$, O-CH₂); 1.03 (t, 6H, $J(\text{CH}_2, \text{CH}_3) = 7.1$, CH₃). ¹³C NMR: 167.22 (C-6); 153.57 (C-2); 150.00 (C-4); 137.16 (C-8); 124.05 (C-5); 99.95 (C-2'); 62.26 (2C, O-CH₂); 45.33 (C-1'); 15.33 (2C, CH₃). FAB MS, m/z : 253 [M + H]. For C₁₁H₁₆N₄O₃ calcd: C, 52.37; H, 6.39; N, 22.21; O, 19.03%; found: C, 52.15; H, 6.49; N, 21.90; O, 19.46%.

9-(2,2-Diethoxyethyl)guanine (6b). The compound (3b) (1.7 g, 6 mmol), K₂CO₃ (3.32 g, 24 mmol) and DABCO (1.34 g, 12 mmol) were dissolved in water (20 mL) and stirred at reflux for 1.5 h, neutralized with Dowex 50 × 8, alkalified with 10% ammonia and filtered. The resin was washed with water (200 mL) and 10% ammonia



(200 mL). The filtrate was evaporated. The crude product was crystallized from water to afford 1.21 g (73%) of compound (**6b**), white solid, mp = 277.7°C (dec.), R_F = 0.75 (S3). ^1H NMR: δ 10.58 (s, 1H, NH); 7.60 (s, 1H, H-8); 6.46 (brs, 2H, NH_2); 4.73 (t, 1H, $J(2',1') = 5.4$, H-2'); 4.01 (d, 2H, $J(1',2') = 5.4$, H-1'); 3.63 and 3.39 (dq, 2H, $J(\text{CH}_2, \text{CH}_3) = 7.1$, $J(\text{gem}) = 9.6$, O- CH_2); 1.04 (t, 6H, $J(\text{CH}_3, \text{CH}_2) = 7.1$, CH_3). ^{13}C NMR: δ 157.01 (C-2); 153.77 (C-6); 151.54 (C-4); 138.06 (C-8); 116.35 (C-5); 99.78 (C-2'); 62.40 (2C, O- CH_2); 45.32 (C-1'); 15.31 (2C, CH_3). FAB MS, m/z : 268.2 [$\text{M} + \text{H}$]. For $\text{C}_{11}\text{H}_{17}\text{N}_5\text{O}_3 \cdot 1/2\text{H}_2\text{O}$ calcd: C, 47.82; H, 6.57; N, 25.35; O, 20.27%; found: C, 47.73; H, 6.44; N, 25.16; O, 20.67%.

9-(2,2-Diethoxyethyl)-6-sulfanylpurine (7a). A solution of compound (**3a**) (2.17 g, 8 mmol) and thiourea (1.9 g, 24 mmol) in ethanol (120 mL) was stirred at reflux for 1.5 h, cooled and made basic with triethylamine. The crystalline product was filtered, washed with ethanol and ether and dried. Yield 1.85 g (86%), white crystals, mp = 241–243°C (dec.), R_F = 0.54 (S2). ^1H NMR: δ 13.75 (brs, 1H, SH); 8.215 (s, 1H, H-2); 8.21 (s, 1H, H-8); 4.82 (t, 1H, $J(2',1') = 5.3$, H-2'); 4.26 (d, 2H, $J(1',2') = 5.3$, H-1'); 3.62 and 3.43 (dq, 2H, $J(\text{CH}_2, \text{CH}_3) = 7.0$, $J(\text{gem}) = 9.6$, O- CH_2); 1.03 (t, 6H, $J(\text{CH}_3, \text{CH}_2) = 7.0$, CH_3). ^{13}C NMR: δ 175.95 (C-6); 145.17 (C-2); 144.48 (C-4); 143.69 (C-8); 134.81 (C-5); 99.53 (C-2'); 62.53 (2C, O- CH_2); 45.74 (C-1'); 15.26 (2C, CH_3). FAB MS, m/z : 269.1 [$\text{M} + \text{H}$]. For $\text{C}_{11}\text{H}_{16}\text{N}_4\text{O}_2\text{S}$ calcd: C, 49.24; H, 6.01; N, 20.88; O, 11.92; S, 11.95%; found: C, 49.03; H, 6.07; N, 20.73; O, 12.25%; S, 11.92%.

2-Amino-9-(2,2-diethoxyethyl)-6-sulfanylpurine (7b). This compound was prepared from compound (**3b**) (1.71 g, 6 mmol) according to the above described procedure for compound (**7a**). Yield 1.56 g (89%) of white crystals, not melting below 300°C, R_F = 0.54 (S2). ^1H NMR: δ 11.88 (s, 1H, SH); 7.80 (s, 1H, H-8); 6.81 (brs, 2H, NH_2); 4.75 (t, 1H, $J(2',1') = 5.2$, H-2'); 4.03 (d, 2H, $J(1',2') = 5.2$, H-1'); 3.63 and 3.41 (dq, 2H, $J(\text{CH}_2, \text{CH}_3) = 7.0$, $J(\text{gem}) = 9.6$, O- CH_2); 1.04 (t, 6H, $J(\text{CH}_3, \text{CH}_2) = 7.0$, CH_3). ^{13}C NMR: 175.01 (C-6); 153.19 (C-2); 148.22 (C-4); 141.13 (C-8); 128.06 (C-5); 99.57 (C-2'); 62.45 (2C, O- CH_2); 45.29 (C-1'); 15.32 (2C, CH_3). FAB MS, m/z : 284 [$\text{M} + \text{H}$]. For $\text{C}_{11}\text{H}_{17}\text{N}_5\text{O}_2\text{S} \cdot 1/2\text{H}_2\text{O}$ calcd: C, 45.19; H, 6.21; N, 23.96; O, 13.68; S, 10.97%; found: C, 45.02; H, 6.11; N, 23.77; O, 13.99; S, 11.11%.

N^6 -Substituted 3-(6-Aminopurin-9-yl)-2-hydroxypropanoic acids and 3-(2,6-Diaminopurin-9-yl)-2-hydroxypropanoic Acids. *General procedure.* A mixture of N^6 -substituted 6-amino- or 2,6-diamino-9-(2,2-diethoxyethyl)purine (5–7) (6 mmol), water (30 mL) and conc. hydrochloric acid (1.2 mL) was heated for 4–8 h at 60°C until the reaction was complete (S2). After cooling to -5°C (ice-salt mixture), potassium cyanide (1.95 g, 30 mmol) was added under stirring, the mixture was rapidly adjusted to pH 6–6.5 with acetic acid and stirred at 0°C for 5 h and at room temperature overnight. Concentrated hydrochloric acid (20 mL) was added, the mixture was refluxed for 6 h, cooled, and evaporated. The residue was deionized on Dowex 50 \times 8 (see above), and purified by Dowex 1 \times 2 column chromatography (see above). Unless otherwise stated, the column was eluted with gradient of acetic



acid (2 L, 0–0.5 M). The crude product was crystallized from water. The following compounds were prepared by this procedure:

3-[6-(Dimethylamino)purin-9-yl]-2-hydroxypropanoic Acid (8a). Pale brown solid, yield 76%, mp = 232°C (dec.), E_{up} = 0.61. ^1H NMR: 12.90 (brs, 1H, COOH); 8.22 (s, 1H, H-2); 8.07 (s, 1H, H-8); 5.90 (brs, 1H, OH); 4.46 (dd, 1H, $J(1'a,2') = 3.9$, $J(\text{gem}) = 13.7$, H-1'a); 4.39 (dd, 1H, $J(2',1'a) = 3.9$, $J(2',1'b) = 8.2$, H-2'); 4.27 (dd, 1H, $J(1'b,2') = 8.2$, $J(\text{gem}) = 13.7$, H-1'b); 3.46 (brs, 6H, N-CH₃). FAB MS m/z : 252 [M + H]. For C₁₀H₁₃N₅O₃·1/2H₂O calcd: C, 46.15; H, 5.42; N, 26.91; O, 21.52%; found: C, 46.11; H, 5.39; N, 26.69; O, 21.81%.

3-[6-(Cyclopropylamino)purin-9-yl]-2-hydroxypropanoic Acid (8b). Crystallized from water-acetone mixture, white solid, yield 80%, mp = 245°C (dec.), E_{up} = 0.50. ^1H NMR: 12.80 (brs, 1H, COOH); 8.24 (s, 1H, H-2); 8.04 (s, 1H, H-8); 7.90 (brs, 1H, NH); 5.90 (brs, 1H, OH); 4.46 (dd, 1H, $J(1'a,2') = 3.6$, $J(\text{gem}) = 13.7$, H-1'a); 4.40 (dd, 1H, $J(2',1'a) = 3.6$, $J(2',1'b) = 8.0$, H-2'); 4.27 (dd, 1H, $J(1'b,2') = 8.0$, $J(\text{gem}) = 13.7$, H-1'b); 3.05 (m, 1H, N-CH); 0.71 and 0.60 (m, 2H, C-CH₂). ^{13}C NMR: 173.36 (C=O); 155.66 (C-6); 152.44 (C-2); 149.30 (C-4); 141.56 (C-8); 68.72 (C-2'); 46.39 (C-1'); 24.02 (N-CH); 6.64 (2C, CH₂). FAB MS m/z : 264 [M + H]. For C₁₁H₁₃N₅O₃ calcd: C, 50.19; H, 4.98; N, 26.60; O, 18.23%; found: C, 49.86; H, 4.98; N, 26.47; O, 18.69%.

2-Hydroxy-3-[6-(pyrrolidin-1-yl)purin-9-yl]propanoic Acid (8c). Pale brown solid, yield 81%, mp = 236°C (dec.), E_{up} = 0.54. ^1H NMR: 12.80 (brs, 1H, COOH); 8.21 (s, 1H, H-2); 8.04 (s, 1H, H-8); 5.80 (brs, 1H, OH); 4.46 (dd, 1H, $J(1'a,2') = 3.9$, $J(\text{gem}) = 13.8$, H-1'a); 4.39 (dd, 1H, $J(2',1'a) = 3.9$, $J(2',1'b) = 8.1$, H-2'); 4.27 (dd, 1H, $J(1'b,2') = 8.1$, $J(\text{gem}) = 13.8$, H-1'b); 4.05 and 3.62 (m, 2H, N-CH₂); 1.97 and 1.93 (m, 2H, C-CH₂). ^{13}C NMR: 173.28 (C=O); 152.42 (C-6); 152.01 (C-2); 150.08 (C-4); 141.10 (C-8); 119.30 (C-5); 68.67 (C-2'); 48.52 and 47.19 (N-CH₂); 46.33 (C-1'); 25.91 and 24.02 (C-CH₂). FAB MS m/z : 278 [M + H]. For C₁₂H₁₅N₅O₃ calcd: C, 51.98; H, 5.45; N, 25.26; O, 17.31%; found: C, 51.90; H, 5.44; N, 25.02; O, 17.64%.

3-[2-Amino-6-(dimethylamino)purin-9-yl]-2-hydroxypropanoic Acid (8d). The resin, after the elution by acetic acid, was stirred with boiling water (1 L), filtered and the water was evaporated. The residue was crystallized from water to afford white solid, yield 67%, mp = 272°C (dec.), E_{up} = 0.47. ^1H NMR: 7.63 (s, 1H, H-8); 5.87 (brs, 2H, NH₂); 4.33 (dd, 1H, $J(2',1'a) = 3.9$, $J(2',1'b) = 8.4$, H-2'); 4.29 (dd, 1H, $J(1'a,2') = 3.9$, $J(\text{gem}) = 13.8$, H-1'a); 4.06 (dd, 1H, $J(1'b,2') = 8.4$, $J(\text{gem}) = 13.8$, H-1'b); 3.35 (brs, 6H, N-CH₃). FAB MS m/z : 267 [M + H]. For C₁₀H₁₄N₆O₃·H₂O calcd: C, 42.25; H, 5.67; N, 29.56; O, 22.51%; found: C, 42.16; H, 5.75; N, 29.20; O, 22.89%.

3-[2-Amino-6-(cyclopropylamino)purin-9-yl]-2-hydroxypropanoic Acid (8e). White solid, yield 82%, mp = 258 – 260°C (dec.), E_{up} = 0.45. ^1H NMR: 7.61 (s, 1H, H-8); 7.36 (brs, 1H, NH); 6.00 (brs, 1H, OH); 5.95 (brs, 2H, NH₂); 4.33 (dd, 1H, $J(2',1'a) = 3.8$, $J(2',1'b) = 8.4$, H-2'); 4.28 (dd, 1H, $J(1'a,2') = 3.8$, $J(\text{gem}) = 13.9$,



H-1'a); 4.06 (dd, 1H, $J(1'b,2') = 8.4$, $J(\text{gem}) = 13.9$, H-1'b); 3.01 (m, 1H, N-CH); 0.65 and 0.57 (m, 2H, C-CH₂). ¹³C NMR: 173.59 (C=O); 160.11 (C-2); 155.97 (C-6); 150.00 (C-4); 138.21 (C-8); 113.32 (C-5); 68.91 (C-2'); 46.11 (C-1'); 28.45 (N-CH); 6.66 (2C, CH₂). FAB MS m/z : 279 [M + H]. For C₁₁H₁₄N₆O₃·1/3H₂O calcd: C, 46.48; H, 5.20; N, 29.56; O, 18.76%; found: C, 46.54; H, 5.22; N, 29.73; O, 18.51%.

3-[2-Amino-6-(pyrrolidin-1-yl)purin-9-yl]-2-hydroxypropanoic Acid (8f). The Dowex 1 × 2 resin, after the elution with acetic acid, was stirred with boiling water (1 L), filtered and the filtrate evaporated. The crude product was crystallized from water. White solid, yield 51%, mp = 275°C (dec.), $E_{\text{Up}} = 0.44$. ¹H NMR: 7.61 (s, 1H, H-8); 5.84 (brs, 2H, NH₂); 4.30 and 4.05 and 4.00 (m, 1H, H-1' and H-2'); 3.70 (m, 4H, N-CH₂); 1.90 (m, 4H, C-CH₂). ¹³C NMR: 173.49 (C=O); 159.87 (C-2); 153.20 (C-6); 152.40 (C-4); 137.82 (C-8); 113.78 (C-5); 68.85 (C-2'); 46.03 (C-1'). FAB MS m/z : 293 [M + H]. For C₁₂H₁₆N₆O₃ calcd: C, 49.31; H, 5.52; N, 28.75; O, 16.42%; found: C, 49.04; H, 5.57; N, 28.60; O, 16.79%.

2-Hydroxy-3-[hypoxanthin-9-yl]propanoic Acid (9a). The Dowex 1 × 2 column was eluted with gradient of acetic acid (2 L, 0–1 M). The resin was then stirred with boiling water (1 L), filtered and stirred with hot acetic acid (1 L, 1.5 M). The aqueous solutions were joined, evaporated and the residue has crystallized from water. White crystals, yield 25%, mp = 112.6°C, $E_{\text{Up}} = 0.72$. ¹H NMR: 12.60 (brs, 1H, COOH); 12.30 (brs, 1H, NH); 8.05 (s, 1H, H-2); 7.99 (s, 1H, H-8); 5.90 (brs, 1H, OH); 4.44 (dd, 1H, $J(1'a,2') = 3.8$, $J(\text{gem}) = 13.7$, H-1'a); 4.37 (dd, 1H, $J(2',1'a) = 3.8$, $J(2',1'b) = 8.3$, H-2'); 4.26 (dd, 1H, $J(1'b,2') = 8.3$, $J(\text{gem}) = 13.7$, H-1'b). ¹³C NMR: 173.20 (C=O); 156.85 (C-6); 148.67 (C-4); 145.69 (C-2); 141.15 (C-8); 123.90 (C-5); 68.87 (C-2'); 46.66 (C-1'). FAB MS m/z : 225 [M + H]. For C₈H₈N₄O₄·H₂O calcd: C, 39.67; H, 4.16; N, 23.13; O, 33.03; found: C, 39.53; H, 4.23; N, 22.93; O, 33.31%.

3-[Guanin-9-yl]-2-hydroxypropanoic Acid (9b). The Dowex 1 × 2 column was eluted with gradient of acetic acid (2 L, 0–1.5 M). White solid, yield 27%, mp = 292°C (dec.), $E_{\text{Up}} = 0.66$. ¹H NMR: 12.50 (brs, 1H, COOH); 10.60 (brs, 1H, NH); 7.61 (s, 1H, H-8); 6.49 (brs, 2H, NH₂); 5.90 (brs, 1H, OH); 4.31 (dd, 1H, $J(2',1'a) = 3.9$, $J(2',1'b) = 8.8$, H-2'); 4.25 (dd, 1H, $J(1'a,2') = 3.9$, $J(\text{gem}) = 13.9$, H-1'a); 4.04 (dd, 1H, $J(1'b,2') = 8.8$, $J(\text{gem}) = 13.9$, H-1'b). ¹³C NMR: 173.39 (C=O); 157.01 (C-2); 153.74 (C-6); 151.42 (C-4); 138.38 (C-8); 116.43 (C-5); 68.83 (C-2'); 46.14 (C-1'). FAB MS m/z : 240 [M + H]. For C₈H₉N₅O₄·1/3H₂O calcd: C, 39.19; H, 3.79; N, 28.56; O, 28.28; found: C, 39.30; H, 4.04; N, 28.18; O, 28.48%.

2-Hydroxy-3-[6-sulfanylpurin-9-yl]propanoic Acid (10a). DMF (5 mL) was added to the reaction mixture to improve solubility. Crystallization from water afforded yellow solid, yield 89%, mp = 220°C (dec.), $E_{\text{Up}} = 0.88$. ¹H NMR: 13.74 (brs, 1H, SH); 12.50 (brs, 1H, COOH); 8.21 (s, 1H, H-2); 8.19 (s, 1H, H-8); 5.90 (brs, 1H, OH); 4.46 (dd, 1H, $J(1'a,2') = 3.9$, $J(\text{gem}) = 13.7$, H-1'a); 4.38 (dd, 1H, $J(2',1'a) = 3.9$, $J(2',1'b) = 8.2$, H-2'); 4.30 (dd, 1H, $J(1'b,2') = 8.2$, $J(\text{gem}) = 13.7$, H-1'b). ¹³C NMR: 175.90 (C-6); 173.08 (C=O); 145.11 (C-2); 144.47 (C-4); 143.88



(C-8); 134.99 (C-5); 68.72 (C-2'); 46.72 (C-1'). FAB MS m/z : 241 $[M+H]$. For $C_8H_8N_4O_3S \cdot H_2O$ calcd: C, 37.21; H, 3.90; N, 21.69; O, 24.78; S, 12.41%; found: C, 37.59; H, 3.77; N, 21.74; O, 24.51; S, 12.39%.

3-[2-Amino-6-sulfanylpurin-9-yl]-2-hydroxypropanoic Acid (10b). DMF (5 mL) was added to the reaction mixture to improve solubility. The resin was, after the elution by acetic acid, stirred with boiling water (1 L), filtered and then stirred with hot acetic acid (1 L, 1 M) and filtered. Water and acetic acid were evaporated. The residue has crystallized from water to afford yellow solid, yield 27%, mp = 284°C (dec.), E_{up} = 0.63. 1H NMR: 12.90 (brs, 1H, SH); 11.88 (brs, 1H, COOH); 7.79 (s, 1H, H-8); 6.82 (brs, 2H, NH_2); 5.90 (brs, 1H, OH); 4.32 (dd, 1H, $J(2',1'a) = 3.9$, $J(2',1'b) = 8.7$, H-2'); 4.26 (dd, 1H, $J(1'a,2') = 3.9$, $J(gem) = 14.0$, H-1'a); 4.07 (dd, 1H, $J(1'b,2') = 8.7$, $J(gem) = 14.0$, H-1'b). ^{13}C NMR: 174.95 (C-6); 173.24 (C=O); 153.15 (C-2); 148.14 (C-4); 141.37 (C-8); 128.20 (C-5); 68.60 (C-2'); 46.12 (C-1'). FAB MS m/z : 256 $[M+H]$. For $C_8H_9N_5O_3S \cdot 1/3H_2O$ calcd: C, 36.78; H, 3.73; N, 26.81; O, 20.41; S, 12.27%; found: C, 37.19; H, 3.70; N, 26.51; O, 20.49; S, 12.11%.

N^6 -Substituted 4-(6-Aminopurin-9-yl)-3-butenic Acids. General procedure. A mixture of N^6 -substituted 6-amino-9-(2,2-diethoxyethyl)purine (**5a–5c**) (2 mmol) and malonic acid (8 mmol) in water (15 mL) was stirring at reflux for 24–32 h. The course of the reaction was checked by TLC in S1 and by electrophoresis. The reaction mixture was cooled to r.t. and the crystalline product was filtered, washed with water and ether and dried over P_2O_5 . The following compounds were prepared:

4-[6-(Dimethylamino)purin-9-yl]-3-butenic Acid (15a). White crystals, yield 0.28 g (60%), mp = 222.8°C, E_{up} = 0.57. 1H NMR: 12.43 (brs, 1H, COOH); 8.46 (s, 1H, H-2); 8.25 (s, 1H, H-8); 7.20 (dt, 1H, $J(1',2') = 14.5$, $J(1',3') = 1.3$, H-1'); 6.63 (dt, 1H, $J(2',1') = 14.5$, $J(2',3') = 7.4$, H-2'); 3.24 (dd, 2H, $J(3',2') = 7.4$, $J(3',1') = 1.3$, H-3'); 3.37 (brs, 6H, CH_3). ^{13}C NMR: 172.64 (C=O); 154.36 (C-6); 152.49 (C-2); 149.44 (C-4); 137.48 (C-8); 123.19 (C-1'); 119.62 (C-5); 113.70 (C-2'); 43.50 and 37.55 (N- CH_3); 35.12 (C-3'). FAB MS, m/z : 248 $[M+H]$. For $C_{11}H_{13}N_5O_2$ calcd: C, 53.44; H, 5.30; N, 28.32; O, 12.94%; found: C, 53.33; H, 5.37; N, 28.15; O, 13.15%.

4-[6-(Cyclopropylamino)purin-9-yl]-3-butenic Acid (15b). Pale yellow crystals, yield 0.36 g (70%), mp = 239°C (dec.), E_{up} = 0.52. 1H NMR: 12.47 (brs, 1H, COOH); 8.44 (s, 1H, H-2); 8.30 (s, 1H, H-8); 8.01 (brs, 1H, N-H); 7.20 (dt, 1H, $J(1',2') = 14.5$, $J(1',3') = 1.3$, H-1'); 6.66 (dt, 1H, $J(2',1') = 14.5$, $J(2',3') = 7.4$, H-2'); 3.24 (dd, 2H, $J(3',2') = 7.4$, $J(3',1') = 1.3$, H-3'); 3.02 (m, 1H, N-CH); 0.73 and 0.62 (m, 2H, C- CH_2). ^{13}C NMR: 172.66 (C=O); 156.02 (C-6); 153.14 (C-2); 149.50 (C-4); 138.74 (C-8); 123.41 (C-1'); 119.62 (C-5); 113.63 (C-2'); 35.15 (C-3'); 27.00 (N-CH); 6.61 (C- CH_2). FAB MS, m/z : 260 $[M+H]$. For $C_{12}H_{13}N_5O_2$ calcd: C, 55.59; H, 5.05; N, 27.01; O, 12.34%; found: C, 55.33; H, 5.17; N, 27.39; O, 12.11%.

4-[6-(Pyrrolidin-1-yl)purin-9-yl]-3-butenic Acid (15c). White crystals, yield 0.37 g (64%), mp = 213°C (dec.), E_{up} = 0.58. 1H NMR: 12.45 (brs, 1H, COOH); 8.42 (s, 1H, H-2); 8.24 (s, 1H, H-8); 7.20 (dt, 1H, $J(1',2') = 14.5$, $J(1',3') = 1.3$,



H-1'); 6.64 (dt, 1H, $J(2',1')=14.5$, $J(2',3')=7.4$, H-2'); 4.01 and 3.62 (m, 2H, N-CH₂); 3.24 (dd, 2H, $J(3',2')=7.4$, $J(3',1')=1.3$, H-3'); 1.95 and 1.91 (m, 2H, C-CH₂). ¹³C NMR: 172.68 (C=O); 152.90 (C-2); 152.62 (C-6); 149.12 (C-4); 137.99 (C-8); 123.30 (C-1'); 119.80 (C-5); 113.53 (C-2'); 48.64 and 47.21 (N-CH₂); 35.14 (C-3'); 25.96 and 23.90 (C-CH₂). FAB MS, *m/z*: 274 [M+H]. For C₁₃H₁₅N₅O₂·2H₂O calcd: C, 50.48; H, 6.19; N, 22.64; O, 20.69%; found: C, 50.77; H, 6.23; N, 22.64; O, 20.36%.

4-(Hypoxanthin-9-yl)-3-butenic Acid (15d). The mixture of compound (6a) (1.13 g, 4.5 mmol) and malonic acid (1.89 g, 18 mmol) in water (30 mL) was refluxed for 24 h and cooled to r.t. The crystalline product was filtered, washed with water and acetone. Recrystallization from water afforded 0.59 g (59%) of white solid, mp = 294°C (dec.), *E*_{Up} = 0.63. ¹H NMR: 12.47 (brs, 2H, COOH and N-H); 8.42 (s, 1H, H-2); 8.11 (s, 1H, H-8); 7.16 (dt, 1H, $J(1',2')=14.5$, $J(1',3')=1.5$, H-1'); 6.58 (dt, 1H, $J(2',1')=14.5$, $J(2',3')=7.4$, H-2'); 3.25 (dd, 2H, $J(3',2')=7.4$, $J(3',1')=1.5$, H-3'). ¹³C NMR: 172.49 (C=O); 156.69 (C-6); 147.35 (C-4); 146.43 (C-2); 138.13 (C-8); 124.67 (C-5); 122.99 (C-1'); 115.00 (C-2'); 35.00 (C-3'). FAB MS, *m/z*: 221 [M+H]. For C₉H₈N₄O₃ calcd: C, 49.09; H, 3.66; N, 25.45; O, 21.80%; found: C, 48.97; H, 3.65; N, 25.28; O, 22.10%.

4-(6-Sulfanylpurin-9-yl)-3-butenic Acid (15e). The solution of compound (7a) (1.9 g, 7 mmol) and malonic acid (3 g, 28 mmol) in water (40 mL) was refluxed for 5 h. The reaction mixture was evaporated and deionized on a column of Dowex 50 × 8 (see above). The crude solid was dissolved in water (10 mL), alkalinized with ammonia and applied on a column of Dowex 1 × 2 (acetate form). The column was eluted with water (500 mL), gradient of acetic acid (2 L, 0–1 M) and then with formic acid (500 mL, 1 M). The UV absorbing fraction of the last eluate was evaporated and codistilled with water (3 × 50 mL). The crystallization from water afforded 0.52 g (30%) of compound (15e). Yellow solid, mp = 225°C (dec.), *E*_{Up} = 0.86. ¹H NMR: 13.90 (brs, 1H, SH); 12.50 (brs, 1H, COOH); 8.62 (s, 1H, H-2); 8.25 (s, 1H, H-8); 7.18 (dt, 1H, $J(1',2')=14.5$, $J(1',3')=1.5$, H-1'); 6.61 (dt, 1H, $J(2',1')=14.5$, $J(2',3')=7.4$, H-2'); 3.26 (dd, 2H, $J(3',2')=7.4$, $J(3',1')=1.5$, H-3'). ¹³C NMR: 176.18 (C-6); 172.46 (C=O); 145.80 (C-2); 143.02 (C-4); 140.83 (C-8); 135.61 (C-5); 122.68 (C-1'); 115.79 (C-2'); 35.00 (C-3'). FAB MS, *m/z*: 237 [M+H]. For C₉H₈N₄O₂S·2/3H₂O calcd: C, 43.54; H, 3.79; N, 22.57; O, 17.19; S, 12.91%; found: C, 43.37; H, 3.69; N, 22.77; O, 17.08; S, 13.09%.

N⁶-Substituted 4-(2,6-Diaminopurin-9-yl)-3-butenic Acids. General procedure. A mixture of N⁶-substituted 2,6-diamino-9-(2,2-diethoxyethyl)purine (5f–5h) (6 mmol) and malonic acid (24 mmol) in water (35 mL) was refluxed for 19–25 h, the course of the reaction was checked on TLC (S2) and by electrophoresis. The reaction mixture was evaporated, deionized on Dowex 50 × 8 (see above). The crude product was purified by Dowex 1 × 2 column chromatography (see above), the column was eluted with gradient of acetic acid (2 L, 0–0.5 M). The UV absorbing eluate was evaporated and codistilled with water (3 × 50 mL). The subsequent



crystallization afforded these compounds:

4-[2-Amino-6-(dimethylamino)purin-9-yl]-3-butenic Acid (15f). White solid, crystallized from water, yield 0.95 g (54%), mp = 241°C (dec.), E_{up} = 0.47. 1H NMR: 12.30 (brs, 1H, COOH); 8.06 (s, 1H, H-8); 7.00 (dt, 1H, $J(1',2') = 14.5$, $J(1',3') = 1.2$, H-1'); 6.44 (dt, 1H, $J(2',1') = 14.5$, $J(2',3') = 7.4$, H-2'); 6.00 (brs, 2H, NH₂); 3.36 (brs, 6H, N-CH₃); 3.18 (dd, 2H, $J(3',2') = 7.4$, $J(3',1') = 1.2$, H-3'). ^{13}C NMR: 172.74 (C=O); 159.68 (C-2); 154.62 (C-6); 151.83 (C-4); 134.09 (C-8); 123.39 (C-1'); 113.86 (C-5); 111.90 (C-2'); 40.29 and 37.90 (N-CH₃); 35.22 (C-3'). FAB MS, m/z: 263 [M + H]. For C₁₁H₁₄N₆O₂ calcd: C, 50.38; H, 5.38; N, 32.04; O, 12.20%; found: C, 50.21; H, 5.35; N, 31.92; O, 12.52%.

4-[2-Amino-6-(cyclopropylamino)purin-9-yl]-3-butenic Acid (15g). White solid, crystallized from water-acetone mixture, yield 0.9 g (50%), mp = 247°C (dec.), E_{up} = 0.41. 1H NMR: 12.43 (brs, 1H, COOH); 8.18 (s, 1H, H-8); 7.50 (brs, 3H, N-H); 7.00 (d, 1H, $J(1',2') = 14.4$, H-1'); 6.49 (dt, 1H, $J(2',1') = 14.4$, $J(2',3') = 7.4$, H-2'); 3.19 (d, 2H, $J(3',2') = 7.4$, H-3'); 2.95 (m, 1H, N-CH); 0.80 and 0.68 (m, 2H, C-CH₂). ^{13}C NMR: 172.63 (C=O); 157.5 (C-2); 153.00 (C-6); 149.99 (C-4); 123.14 (C-1'); 113.26 (C-5); 112.84 (C-2'); 35.19 (C-3'); 24.11 (N-CH); 7.08 (2C, CH₂). FAB MS, m/z: 275 [M + H]. For C₁₂H₁₄N₆O₂·3/2H₂O calcd: C, 47.84; H, 5.69; N, 27.89; O, 18.58%; found: C, 48.15; H, 5.33; N, 27.76; O, 18.76%.

4-[2-Amino-6-(pyrrolidin-1-yl)purin-9-yl]-3-butenic Acid (15h). White solid, crystallized from water-ethanol mixture, yield 0.6 g (35%), mp = 259°C, E_{up} = 0.39. 1H NMR: 12.40 (brs, 1H, COOH); 8.01 (s, 1H, H-8); 7.00 (dt, 1H, $J(1',2') = 14.5$, $J(1',3') = 1.0$, H-1'); 6.44 (dt, 1H, $J(2',1') = 14.5$, $J(2',3') = 7.1$, H-2'); 5.92 (brs, 2H, NH₂); 3.95 and 3.55 (m, 2H, N-CH₂); 3.17 (d, 2H, $J(3',2') = 7.1$, H-3'); 1.91 (m, 4H, C-CH₂). ^{13}C NMR: 172.78 (C=O); 160.27 (C-2); 153.13 (C-6); 151.54 (C-4); 134.48 (C-8); 123.51 (C-1'); 114.14 (C-5); 111.61 (C-2'); 48.60 and 47.50 (N-CH₂); 35.25 (C-3'); 25.50 and 25.0 (C-CH₂). FAB MS, m/z: 289 [M + H]. For C₁₃H₁₆N₆O₂·1/2H₂O calcd: C, 52.52; H, 5.76; N, 28.27; O, 13.45%; found: C, 52.79; H, 5.73; N, 28.17; O, 13.31%.

4-(Guanin-9-yl)-3-butenic Acid (15i). This compound was prepared by the same procedure as compound (15d) from compound (6b) (1.2 g, 4.5 mmol), white solid, yield 0.63 g (60%), mp = 306°C (dec.), E_{up} = 0.52. 1H NMR: 12.45 (brs, 1H, COOH); 10.71 (s, 1H, N-H); 8.02 (s, 1H, H-8); 6.93 (dt, 1H, $J(1',2') = 14.5$, $J(1',3') = 1.5$, H-1'); 6.56 (brs, 2H, NH₂); 6.41 (dt, 1H, $J(2',1') = 14.5$, $J(2',3') = 7.4$, H-2'); 3.17 (dd, 2H, $J(3',2') = 7.4$, $J(3',1') = 1.5$, H-3'). ^{13}C NMR: 172.69 (C=O); 156.85 (C-2); 154.11 (C-6); 150.31 (C-4); 135.08 (C-8); 123.19 (C-1'); 117.06 (C-5); 113.03 (C-2'); 35.17 (C-3'). FAB MS, m/z: 236 [M + H]. For C₉H₉N₅O₃ calcd: C, 45.96; H, 3.86; N, 29.78; O, 20.41%; found: C, 45.61; H, 3.89; N, 29.74; O, 20.76%.

4-(2-Amino-6-sulfanylpurin-9-yl)-3-butenic Acid (15j). This compound was prepared from compound (7b) (0.98 g, 7 mmol) by the same procedure as the compound (15e). Crystallization from water afforded 0.76 g (42%) of yellow solid, mp = 259°C (dec.), E_{up} = 0.67. 1H NMR: 12.48 (brs, 1H, COOH); 12.01 (s, 1H, SH);



8.21 (s, 1H, H-8); 6.94 (dt, 1H, $J(1',2') = 14.5$, $J(1',3') = 1.0$, H-1'); 6.88 (brs, 2H, NH₂); 6.46 (dt, 1H, $J(2',1') = 14.5$, $J(2',3') = 7.4$, H-2'); 3.19 (dd, 2H, $J(3',2') = 7.4$, $J(3',1') = 1.0$, H-3'). ¹³C NMR: 175.30 (C-6); 172.55 (C=O); 153.43 (C-2); 146.80 (C-4); 138.13 (C-8); 128.65 (C-5); 122.84 (C-1'); 113.86 (C-2'); 35.14 (C-3'). FAB MS, m/z: 252 [M + H]. For C₉H₉N₅O₂S.1/2H₂O calcd: C, 41.53; H, 3.87; N, 26.91; O, 15.37; S, 12.32%; found: C, 41.87; H, 3.83; N, 26.53; O, 15.34; S, 12.43%.

ACKNOWLEDGMENTS

This study was performed as a part of research project # 4055905 of the Institute of Organic Chemistry and Biochemistry. It was supported by the Programme of Targeted Projects of the Academy of Sciences of the Czech Republic (# S4055109), by the René Descartes Prize-2001 of the European Commission, by COST programme 13.20 of the Ministry of Education of the Czech Republic and by Gilead Sciences (Foster City, CA, USA). The authors' thanks are due to Professor E. De Clercq and his group in the Rega Institute, Katholic University Leuven (Belgium) for the evaluation of antiviral activity, to Dr. I. Votruba of the Institute of Organic Chemistry and Biochemistry for the estimation of cytostatic activity and to the staff of the mass spectrometry and analytical departments of this Institute (Head, K. Ubik) for elemental analyses and measuring of mass spectra.

REFERENCES

1. Holý, A.; Votruba, I.; De Clercq, E. Structure-activity studies on open-chain analogues of nucleosides: inhibition of S-adenosyl-L-homocysteine hydrolase and antiviral activity. 2. Acid open-chain analogues. Collect. Czech. Chem. Commun. **1985**, 50, 262–279.
2. Holý, A.; Votruba, I.; Merta, A.; De Clercq, E.; Jelínek, R.; Sláma, K.; Beneš, K.; Melichar, O. Biological consequences of S-adenosyl-L-homocysteinase inhibition by acyclic adenosine analogs. In *Biological Methylation and Drug Design*; Borchardt, R.R., Creveling, C.R., Ueland, P.M., Eds.; Humana Press: Clifton, 1986; 397–408.
3. Sláma, K.; Holý, A. Sterilization of *Pyrrhocoris apterus* by open-chain nucleoside analogues: Dose-response and structure-activity relationship. Acta entomol. Bohemoslov. **1988**, 85, 94–106.
4. Beneš, K.; Holý, A.; Melichar, O.; Rosenberg, I. The effect of some 9-substituted adenine derivatives on the development of seedling roots of broad bean. Biol. plant. **1984**, 26, 144–150.
5. De Clercq, E.; Holý, A. Alkyl esters of 3-adenin-9-yl-2-hydroxypropanoic acid: A new class of broad-spectrum antiviral agents. J. Med. Chem. **1985**, 28, 282–287.
6. Schuster, G.; Holý, A. Inhibitory effects of 9-(2,3-dihydroxypropyl)adenine and 3-(adenin-9-yl)-2-hydroxypropanoic acid 2-methylpropylester on potato virus X replication. Antiviral Res. **1988**, 9, 329–334.



7. Votruba, I.; Hasobe, M.; Holý, A.; Borchardt, R.T. 2-Methylpropyl ester of 3-(adenin-9-yl)-2-hydroxypropanoic acid. Mechanism of antiviral action in vaccinia virus-infected L929 cells. *Biochem. Pharmacol.* **1990**, *39*, 1573–1580.
8. Krečmerová, M.; Buděšínský, M.; Masojídková, M.; Holý, A. Synthesis of optically active N⁶-alkyl derivatives of (2R)-3-(adenin-9-yl)-2-hydroxypropanoic acid and related compounds. *Collect. Czech. Chem. Commun.* **2003**, *68*, 931–950.
9. Holý, A. Preparation and synthetic utilization of 3-(adenin-9-yl)-2-hydroxyalkanoic acids and their derivatives. *Collect. Czech. Chem. Commun.* **1984**, *49*, 2148–2166.
10. (a) Holý, A.; Votruba, I.; Tloušťová, E.; Masojídková, M. Synthesis and cytostatic activity of N-[2-(phosphonomethoxy)alkyl] derivatives of N⁶-substituted adenines, 2,6-diaminopurines and related compounds. *Collect. Czech. Chem. Commun.* **2001**, *66*, 1545–1592; (b) Holý, A.; Günter, J.; Dvořáková, H.; Masojídková, M.; Andrei, G.; Snoeck, R.; Balzarini, J.; De Clercq, E. Structure–antiviral activity relationship in the series of pyrimidine and purine N-[2-(phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base. *J. Med. Chem.* **1999**, *42* (12), 2064–2086.
11. (a) Yamanaka, H.; Yokoyama, M.; Sakamoto, T.; Shiraishi, T.; Sagi, M.; Mizugaki, M. Influence of heteroaromatic amines to Knoevenagel condensation. *Heterocycles* **1983**, *20* (8), 1541–1544; (b) Bulugahapitiya, P.; Landais, Y.; Parra-Papado, L.; Planchenault, D.; Weber, V. A stereospecific access to allylic systems using rhodium(II)-vinyl carbenoid insertion into Si-H, O-H, and N-H bonds. *J. Org. Chem.* **1997**, *62*, 1630–1641.

Received July 25, 2003

Accepted August 29, 2003